GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (FRA:Q8T) » Definitions » Altman Z-Score

OrbusNeich Medical Group Holdings (FRA:Q8T) Altman Z-Score : 8.41 (As of Mar. 27, 2025)


View and export this data going back to 2023. Start your Free Trial

What is OrbusNeich Medical Group Holdings Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 7.42 is strong.

OrbusNeich Medical Group Holdings has a Altman Z-Score of 8.41, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for OrbusNeich Medical Group Holdings's Altman Z-Score or its related term are showing as below:

FRA:Q8T' s Altman Z-Score Range Over the Past 10 Years
Min: 7.42   Med: 16.62   Max: 20.81
Current: 7.42

During the past 6 years, OrbusNeich Medical Group Holdings's highest Altman Z-Score was 20.81. The lowest was 7.42. And the median was 16.62.


OrbusNeich Medical Group Holdings Altman Z-Score Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings Altman Z-Score Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Altman Z-Score
Get a 7-Day Free Trial - - 20.81 12.42 -

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.81 - 12.42 - -

Competitive Comparison of OrbusNeich Medical Group Holdings's Altman Z-Score

For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OrbusNeich Medical Group Holdings's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where OrbusNeich Medical Group Holdings's Altman Z-Score falls into.


';

OrbusNeich Medical Group Holdings Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

OrbusNeich Medical Group Holdings's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.7673+1.4*-0.0899+3.3*0.0989+0.6*11.5088+1.0*0.3807
=8.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was €411.6 Mil.
Total Current Assets was €345.2 Mil.
Total Current Liabilities was €29.3 Mil.
Retained Earnings was €-37.0 Mil.
Pre-Tax Income was €40.5 Mil.
Interest Expense was €-0.2 Mil.
Revenue was €156.7 Mil.
Market Cap (Today) was €402.6 Mil.
Total Liabilities was €35.0 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(345.191 - 29.34)/411.615
=0.7673

X2=Retained Earnings/Total Assets
=-37.013/411.615
=-0.0899

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(40.499 - -0.208)/411.615
=0.0989

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=402.634/34.985
=11.5088

X5=Revenue/Total Assets
=156.713/411.615
=0.3807

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

OrbusNeich Medical Group Holdings has a Altman Z-Score of 8.41 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


OrbusNeich Medical Group Holdings  (FRA:Q8T) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


OrbusNeich Medical Group Holdings Altman Z-Score Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


OrbusNeich Medical Group Holdings Business Description

Traded in Other Exchanges
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.

OrbusNeich Medical Group Holdings Headlines

No Headlines